San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers' stock price has swung wildly this year. The telehealth company's public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday. On Friday, Hims ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...